MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/mr/road066

Медицинская библиотека · Modern rheumatology · 2024

Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease-modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data.

Higuchi Tomoaki, Tanaka Eiichi, Inoue Eisuke, Abe Mai, Saka Kumiko, Sugano Eri, Sugitani Naohiro, Higuchi Yoko, Ochiai Moeko, Yamaguchi Rei, Ikari Katsunori, Yamanaka Hisashi, Harigai Masayoshi

СтатьяВалидационное исследованиеПеревод пока не подготовлен

Аннотация

OBJECTIVES

This article aims to examine the ability of the Rheumatoid Arthritis Observation of Biologic Therapy (RABBIT) risk score to predict the occurrence of serious infections in Japanese patients with rheumatoid arthritis (RA), after initiating their first biologic disease-modifying antirheumatic drug (bDMARD).

METHODS

We used data from the Institute of Rheumatology, Rheumatoid Arthritis cohort from 2008 to 2020. Patients with RA who were started on their first bDMARDs were included. Those with missing data required to calculate the score were excluded. A receiver operating characteristic curve was used to evaluate the discriminatory ability of the RABBIT score.

RESULTS

A total of 1081 patients were enrolled. During the 1-year observational period, 23 (1.7%) patients had serious infections; the most frequent one was bacterial pneumonia (n = 11, 44%). The median RABBIT score in the serious infection group was significantly higher than that in the non-serious infection group [2.3 (1.5-5.4) vs 1.6 (1.2-2.5), P < .001]. The area under the receiver operating characteristic curve for the occurrence of serious infections was 0.67 (95% confidence interval 0.52-0.79), suggesting that the score had low accuracy.

CONCLUSIONS

Our present study revealed that the RABBIT risk score did not have sufficient discriminatory ability for predicting the development of severe infections in Japanese patients with RA after initiating their first bDMARD.

Для цитирования: Higuchi Tomoaki, Tanaka Eiichi, Inoue Eisuke, Abe Mai, Saka Kumiko, Sugano Eri, Sugitani Naohiro, Higuchi Yoko, Ochiai Moeko, Yamaguchi Rei, Ikari Katsunori, Yamanaka Hisashi, Harigai Masayoshi. Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease-modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data.. Modern rheumatology. 2024. DOI: 10.1093/mr/road066.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.